Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status [Yahoo! Finance]
Better Therapeutics, Inc. (BTTX)
Company Research
Source: Yahoo! Finance
Designation from the FDA to treat people with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. The breakthrough status is significant for the company as technologies achieving Breakthrough Device Designation show promise for outperforming the existing standard of care for patients with severe or life-threatening diseases. Price Performance For the past six months, BTTX's shares have lost 73.9% against the industry's rise of 5.8%. The S&P 500 increased 12.8% in the same time frame. Image Source: Zacks Investment Research More on MASH MASH is an advanced stage of the disease related to the rising rates of diabetes and obesity. However, 16.5 million persons in America have been diagnosed with serious liver problems, including MASH. It is believed that one in four adults in the country suffer from MASLD1. MASH is a major contributor to liver-related mortality and a growing global burden on healthcare systems. Patients with MASH are also more l
Show less
Read more
Impact Snapshot
Event Time:
BTTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTTX alerts
High impacting Better Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTTX
News
- Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers [Yahoo! Finance]Yahoo! Finance
- Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health CentersBusiness Wire
- Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) [Yahoo! Finance]Yahoo! Finance
- Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)Business Wire
- Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire
BTTX
Earnings
- 8/9/23 - Beat
BTTX
Sec Filings
- 3/21/24 - Form 424B3
- 3/21/24 - Form 8-K
- 3/15/24 - Form 424B3
- BTTX's page on the SEC website